查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1808861

尿路上皮癌诊断市场，依检测类型、癌症类型、最终用户、国家及地区划分－2025 年至 2032 年全球产业分析、市场规模、市场份额及预测

Urothelial Carcinoma Diagnostics Market, By Test Type, By Cancer Type, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 355 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年尿路上皮癌诊断市场规模价值 19.8776 亿美元，2025 年至 2032 年的复合年增长率为 9.8%。

尿路上皮癌诊断市场专注于用于检测和监测尿路上皮癌的工具、检测和技术。尿路上皮癌是一种常见的膀胱癌，会影响泌尿道内壁。该市场的诊断方法包括尿液细胞学检查、膀胱镜检查、影像学检查（CT、MRI）以及分子检测，例如萤光原位杂交 (FISH) 和 NMP22 蛋白检测。早期检测至关重要，因为它可以改善治疗效果并降低疾病进展风险。膀胱癌发病率的上升、认知度的提高以及对非侵入性检测方法日益增长的需求推动着市场的发展。

液体活检和基于生物标誌物的检测等技术进步进一步推动了市场成长。医院、诊断实验室和研究机构是主要的终端使用者。北美凭藉其强大的医疗基础设施和较高的诊断率占据市场主导地位。监管部门的批准以及检测灵敏度和特异性方面的创新持续塑造着市场格局。

尿路上皮癌诊断市场-市场动态

提高对永续成长的认识以推动市场需求

尿路上皮癌诊断市场的一个利基驱动因素是尿液生物标记在早期非侵入性膀胱癌检测中的应用日益广泛。膀胱镜检查等传统诊断工具具有侵入性，患者操作不便，且价格昂贵。相较之下，尿液生物标记提供了一种侵入性较低、更方便患者的尿路上皮癌诊断方法。这些生物标记可以检测尿液样本中的基因突变、蛋白质水平和其他分子变化，从而提示是否有癌症。

NMP22、UroVysion (FISH) 和膀胱肿瘤抗原 (BTA) 等检测在临床监测和初步诊断的应用日益广泛。这些检测更加便捷，可重复检测，并在许多情况下减少了侵入性操作的需求。对于因膀胱癌高復发率而需要频繁监测的患者而言，这一趋势尤其重要。

此外，基因组学和蛋白​​质组学的进展正在推动发现新的尿液生物标记物，其灵敏度和特异性均有所提高。这些创新提高了诊断的准确性，使其成为早期癌症检测的宝贵工具。随着精准医疗日益受到重视，医疗保健提供者正在寻求可靠且经济高效的诊断解决方案，这进一步推动了向尿液生物标记检测的转变。这种日益增长的偏好正在塑造尿路上皮癌诊断的未来，尤其是在门诊和资源受限的环境中。

尿路上皮癌诊断市场－关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 9.8%。

根据测试类型细分，膀胱镜检查预计将在 2024 年占据最大市场份额

根据癌症类型细分，非肌肉层浸润性膀胱癌是 2024 年的主要癌症类型

根据最终用户细分，医院是 2024 年的主要最终用户

按地区划分，北美是 2024 年的主要收入来源

尿路上皮癌诊断市场-細項分析：

全球尿路上皮癌诊断市场根据测试类型、癌症类型、最终用户和地区进行细分。

根据检测类型，市场分为五类：尿液细胞学检查、膀胱镜检查、免疫测定、萤光原位杂交 (FISH)、生物标记检测、PCR 检测及其他。按检测类型划分，尿路上皮癌诊断市场中最主要的细分市场是膀胱镜检查。由于其准确性高，并且能够直观地检查膀胱内壁是否存在肿瘤，该检查仍然是诊断和监测膀胱癌的黄金标准。儘管膀胱镜检查属于侵入性检查，但如果发现可疑病变，则可以进行活检并立即进行干预。临床医生高度依赖膀胱镜检查，尤其是对于復发性或高风险膀胱癌患者，这使其成为诊断领域的领先地位。膀胱镜检查已确立的临床实用性以及在医院和泌尿外科中心的广泛应用巩固了其主导地位。

根据癌症类型，市场分为两类：非肌肉浸润性膀胱癌 (NMIBC) 和肌肉层浸润性膀胱癌 (MIBC)。在尿路上皮癌诊断市场中，依癌症类型划分，最主要的细分市场是非肌肉层浸润性膀胱癌 (NMIBC)。 NMIBC 占初次诊断膀胱癌病例的大多数，因此早期和反覆的诊断检测至关重要。由于 NMIBC 患者復发率高，他们通常需要定期监测，这促使他们经常使用膀胱镜检查、尿液细胞学检查和生物标记检测等诊断工具。这种持续的监测显着增加了该细分市场对诊断产品的需求，使 NMIBC 成为市场成长的主要动力。

尿路上皮癌诊断市场—地理洞察

北美地区尿路上皮癌诊断市场格局以强大的医疗基础设施、较高的癌症筛检率以及先进诊断技术的快速普及为特征。美国凭藉其膀胱癌的高发病率、健全的报销体係以及积极的肿瘤诊断研究经费，在该地区处于领先地位。 FDA 等机构的监管支持加速了基于新型生物标记和分子诊断检测的批准和商业化。

加拿大也贡献良多，这得益于人们日益增长的认知度以及政府支持早期癌症检测的措施。该地区的主要参与者经常与学术机构和医院合作，开发和试行创新的诊断解决方案。由于完善的诊断实验室网路和高度集中的精准医疗计划，北美市场已成为尖端尿路上皮癌诊断技术的枢纽。

尿路上皮癌诊断市场-竞争格局：

尿路上皮癌诊断市场的竞争格局由老牌诊断巨头和创新生物技术公司共同构成。罗氏诊断、雅培和赛默飞世尔科技等公司凭藉全面的诊断产品组合、全球终端用户网路和雄厚的研发投入，占据了市场主导地位。这些公司提供先进的分子和免疫分析检测，通常与数位病理学和实验室自动化解决方案捆绑销售，使其在大型医疗保健系统中占据战略优势。

同时，Myriad Genetics、Natera 和 Biocept 等专业公司专注于精准诊断，尤其是膀胱癌的液体活检和基因组分析，为市场注入了活力。这些公司正在利用新一代定序 (NGS)、尿液生物标记和人工智慧的进步来提高诊断的灵敏度和特异性。他们的创新满足了人们对非侵入性、精准且患者友好的诊断日益增长的需求，尤其是在高风险和復发病例中。

最新动态：

2024年6月，ALX Oncology Holdings Inc. 在2024年美国临床肿瘤学会 (ASCO) 年会上透过壁报展示（摘要编号#4575）分享了其1期ASPEN-07临床试验的结果。此资料是首次通报evorpacept与抗体药物偶联物（具体为PADCEV (enfortumab vedotin)）合併用药，研究正在进行一项开放标籤、单组试验，受试者为局部晚期或转移性尿路上皮癌患者。

目录

第一章：尿路上皮癌诊断市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 尿路上皮癌诊断市场片段（依检验类型）
    • 尿路上皮癌诊断市场（按癌症类型）
    • 尿路上皮癌诊断市场片段（依最终用户）
    • 尿路上皮癌诊断市场（按国家/地区）
    • 尿路上皮癌诊断市场（按地区）
  • 竞争洞察

第三章：尿路上皮癌诊断主要市场趋势

  • 尿路上皮癌诊断市场驱动因素
    • 市场驱动因素的影响分析
  • 尿路上皮癌诊断市场限制
    • 市场限制的影响分析
  • 尿路上皮癌诊断市场机会
  • 尿路上皮癌诊断市场未来趋势

第四章：尿路上皮癌诊断产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：尿路上皮癌诊断市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：尿路上皮癌诊断市场格局

  • 2024年尿路上皮癌诊断市占分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：尿路上皮癌诊断市场－依检测类型

  • 概述
    • 按测试类型分類的细分市场份额分析
    • 尿液细胞学检查
    • 膀胱镜检查
    • 免疫测定
    • 萤光原位杂交（FISH）
    • 生物标记测试
    • 基于PCR的检测
    • 其他的

第 8 章：尿路上皮癌诊断市场 - 按癌症类型

  • 概述
    • 按癌症类型分類的细分份额分析
    • 非肌肉层浸润性膀胱癌（NMIBC）
    • 肌肉层浸润性膀胱癌（MIBC）

第九章：尿路上皮癌诊断市场－按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院
    • 诊断实验室
    • 癌症研究机构
    • 门诊手术中心
    • 学术与研究中心

第 10 章：尿路上皮癌诊断市场 - 按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美尿路上皮癌诊断主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测（按测试类型）
    • 北美市场规模及预测（按癌症类型）
    • 北美市场规模及预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲尿路上皮癌诊断主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模和预测（按测试类型）
    • 欧洲市场规模及预测（按癌症类型）
    • 欧洲市场规模及预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区尿路上皮癌诊断主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依测试类型）
    • 亚太地区市场规模及预测（依癌症类型）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲尿路上皮癌诊断主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按测试类型）
    • 拉丁美洲市场规模及预测（按癌症类型）
    • 拉丁美洲市场规模及预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲尿路上皮癌诊断主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依测试类型）
    • MEA 市场规模及预测（以癌症类型）
    • MEA 市场规模及预测（依最终用户）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 11 章：关键供应商分析-尿路上皮癌诊断产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Roche Diagnostics
    • Abbott Laboratories
    • Thermo Fisher Scientific
    • Qiagen
    • Bio-Rad Laboratories
    • Illumina, Inc.
    • Hologic, Inc.
    • Agilent Technologies
    • Myriad Genetics
    • Danaher Corporation
    • Siemens Healthineers
    • Sysmex Corporation
    • Becton, Dickinson and Company (BD)
    • Genomic Health
    • Epigenomics AG
    • Bio-Techne Corporation
    • Natera, Inc.
    • Guardant Health
    • Exact Sciences Corporation
    • Biocept, Inc.

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5515

Urothelial Carcinoma Diagnostics Market size was valued at US$ 1,987.76 Million in 2024, expanding at a CAGR of 9.8% from 2025 to 2032.

The Urothelial Carcinoma Diagnostics Market focuses on the tools, tests, and technologies used to detect and monitor urothelial carcinoma, a common type of bladder cancer affecting the urinary tract's lining. Diagnostics in this market include urine cytology, cystoscopy, imaging techniques (CT, MRI), and the molecular tests such as fluorescence in situ hybridization (FISH) and NMP22 protein tests. Early detection is vital as it improves treatment outcomes and reduces disease progression risks. The market is driven by the rising incidence of bladder cancer, increasing awareness, and growing demand for non-invasive testing methods.

Technological advancements like liquid biopsy and biomarker-based tests are further fueling growth. Hospitals, diagnostic labs, and research institutions are the main end users. North America dominates the market due to strong healthcare infrastructure and high diagnostic rates. Regulatory approvals and innovation in test sensitivity and specificity continue to shape the market landscape.

Urothelial Carcinoma Diagnostics Market- Market Dynamics

Increasing awareness about sustainable growth to propel market demand

One niche driver of the Urothelial Carcinoma Diagnostics Market is the rising adoption of urinary biomarkers for early, non-invasive bladder cancer detection. Traditional diagnostic tools like cystoscopy are invasive, uncomfortable for patients, and costly. In contrast, urinary biomarkers offer a less invasive and more patient-friendly alternative for identifying urothelial carcinoma. These biomarkers can detect genetic mutations, protein levels, and other molecular changes in urine samples that indicate the presence of cancer.

Tests like NMP22, UroVysion (FISH), and bladder tumor antigen (BTA) are increasingly being used in clinical settings for surveillance and initial diagnosis. They provide a higher level of convenience, enable repeat testing, and reduce the need for invasive procedures in many cases. This trend is particularly significant for patients requiring frequent monitoring due to high recurrence rates of bladder cancer.

Additionally, advances in genomics and proteomics are leading to the discovery of new urinary biomarkers with improved sensitivity and specificity. These innovations enhance diagnostic accuracy, making them valuable tools for early-stage cancer detection. As precision medicine becomes more prominent, healthcare providers are seeking reliable, cost-effective diagnostic solutions, further supporting the shift toward urine-based biomarker testing. This growing preference is helping shape the future of urothelial carcinoma diagnostics, especially in outpatient and resource-constrained settings.

Urothelial Carcinoma Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.8% over the forecast period (2025-2032)

Based on Test Type segmentation, Cystoscopy was predicted to show maximum market share in the year 2024

Based on Cancer Type segmentation, Non-Muscle Invasive Bladder Cancer was the leading Cancer Type in 2024

Based on end-user segmentation, Hospitals was the leading end-user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Urothelial Carcinoma Diagnostics Market- Segmentation Analysis:

The Global Urothelial Carcinoma Diagnostics Market is segmented on the basis of Test Type, Cancer Type, End-user, and Region.

The market is divided into five categories based on Test Type: Urine Cytology, Cystoscopy, Immunoassays, Fluorescence in Situ Hybridization (FISH), Biomarker Tests, PCR-Based Tests, and Others. The most dominant segment in the Urothelial Carcinoma Diagnostics Market by test type is Cystoscopy. This procedure remains the gold standard for diagnosing and monitoring bladder cancer due to its high accuracy and ability to visually inspect the bladder lining for tumors. Despite being invasive, it allows for biopsy and immediate intervention if suspicious lesions are detected. Clinicians rely heavily on cystoscopy, especially in patients with recurrent or high-risk bladder cancer, contributing to its leading position in the diagnostics landscape. Its established clinical utility and widespread adoption in hospitals and urology centers solidify its dominance.

The market is divided into two categories based on Cancer Type: Non-Muscle Invasive Bladder Cancer (NMIBC), Muscle Invasive Bladder Cancer (MIBC). The most dominant segment by cancer type in the Urothelial Carcinoma Diagnostics Market is Non-Muscle Invasive Bladder Cancer (NMIBC). NMIBC accounts for the majority of bladder cancer cases at initial diagnosis, making early and repeated diagnostic testing essential. Patients with NMIBC often undergo regular surveillance due to high recurrence rates, driving frequent use of diagnostic tools such as cystoscopy, urine cytology, and biomarker tests. This ongoing monitoring significantly increases the demand for diagnostics in this segment, making NMIBC the leading contributor to market growth.

Urothelial Carcinoma Diagnostics Market- Geographical Insights

The North American regional landscape for the Urothelial Carcinoma Diagnostics Market is marked by strong healthcare infrastructure, high cancer screening rates, and rapid adoption of advanced diagnostic technologies. The United States leads the region due to a high prevalence of bladder cancer, robust reimbursement systems, and active research funding for oncology diagnostics. Regulatory support from bodies like the FDA accelerates the approval and commercialization of novel biomarker-based and molecular diagnostic tests.

Canada also contributes steadily, driven by growing awareness and government initiatives supporting early cancer detection. Key players in the region frequently collaborate with academic institutions and hospitals to develop and pilot innovative diagnostic solutions. The market benefits from a well-established network of diagnostic laboratories and a high concentration of precision medicine initiatives, making North America a hub for cutting-edge urothelial carcinoma diagnostic advancements.

Urothelial Carcinoma Diagnostics Market- Competitive Landscape:

The competitive landscape of the Urothelial Carcinoma Diagnostics Market is shaped by the presence of established diagnostics giants alongside innovative biotech firms. Companies like Roche Diagnostics, Abbott, and Thermo Fisher Scientific dominate the market with comprehensive diagnostic portfolios, global End-user networks, and high R&D investment. These firms offer advanced molecular and immunoassay-based tests, often bundled with digital pathology and laboratory automation solutions, giving them a strategic edge in large healthcare systems.

Meanwhile, specialized companies such as Myriad Genetics, Natera, and Biocept are contributing to market dynamism by focusing on precision diagnostics, especially liquid biopsy and genomic profiling for bladder cancer. These firms are leveraging advancements in next-generation sequencing (NGS), urinary biomarkers, and artificial intelligence to improve diagnostic sensitivity and specificity. Their innovations cater to the growing demand for non-invasive, accurate, and patient-friendly diagnostics, especially for high-risk and recurrent cases.

Recent Developments:

In June 2024, ALX Oncology Holdings Inc. shared results from its Phase 1 ASPEN-07 clinical trial through a poster presentation (abstract #4575) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The data marked the first report of evorpacept used in combination with an antibody-drug conjugate, specifically PADCEV (enfortumab vedotin), in an ongoing open-label, single-arm trial involving patients with locally advanced or metastatic urothelial carcinoma.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Qiagen
  • Bio-Rad Laboratories
  • Illumina, Inc.
  • Hologic, Inc.
  • Agilent Technologies
  • Myriad Genetics
  • Danaher Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Becton, Dickinson and Company (BD)
  • Genomic Health
  • Epigenomics AG
  • Bio-Techne Corporation
  • Natera, Inc.
  • Guardant Health
  • Exact Sciences Corporation
  • Biocept, Inc.

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

  • Urine Cytology
  • Cystoscopy
  • Immunoassays
  • Fluorescence In Situ Hybridization (FISH)
  • Biomarker Tests
  • PCR-Based Tests
  • Others

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Non-Muscle Invasive Bladder Cancer (NMIBC)
  • Muscle Invasive Bladder Cancer (MIBC)

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Academic & Research Centers

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Urothelial Carcinoma Diagnostics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Urothelial Carcinoma Diagnostics Market Snippet by Test Type
    • 2.1.2. Urothelial Carcinoma Diagnostics Market Snippet by Cancer Type
    • 2.1.3. Urothelial Carcinoma Diagnostics Market Snippet by End-user
    • 2.1.4. Urothelial Carcinoma Diagnostics Market Snippet by Country
    • 2.1.5. Urothelial Carcinoma Diagnostics Market Snippet by Region
  • 2.2. Competitive Insights

3. Urothelial Carcinoma Diagnostics Key Market Trends

  • 3.1. Urothelial Carcinoma Diagnostics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Urothelial Carcinoma Diagnostics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Urothelial Carcinoma Diagnostics Market Opportunities
  • 3.4. Urothelial Carcinoma Diagnostics Market Future Trends

4. Urothelial Carcinoma Diagnostics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Urothelial Carcinoma Diagnostics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Urothelial Carcinoma Diagnostics Market Landscape

  • 6.1. Urothelial Carcinoma Diagnostics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Urothelial Carcinoma Diagnostics Market - By Test Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Test Type, 2024 & 2032 (%)
    • 7.1.2. Urine Cytology
    • 7.1.3. Cystoscopy
    • 7.1.4. Immunoassays
    • 7.1.5. Fluorescence In Situ Hybridization (FISH)
    • 7.1.6. Biomarker Tests
    • 7.1.7. PCR-Based Tests
    • 7.1.8. Others

8. Urothelial Carcinoma Diagnostics Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
    • 8.1.2. Non-Muscle Invasive Bladder Cancer (NMIBC)
    • 8.1.3. Muscle Invasive Bladder Cancer (MIBC)

9. Urothelial Carcinoma Diagnostics Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Diagnostic Laboratories
    • 9.1.4. Cancer Research Institutes
    • 9.1.5. Ambulatory Surgical Centers
    • 9.1.6. Academics & Research Centers

10. Urothelial Carcinoma Diagnostics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Urothelial Carcinoma Diagnostics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Urothelial Carcinoma Diagnostics Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Roche Diagnostics
    • 11.2.2. Abbott Laboratories
    • 11.2.3. Thermo Fisher Scientific
    • 11.2.4. Qiagen
    • 11.2.5. Bio-Rad Laboratories
    • 11.2.6. Illumina, Inc.
    • 11.2.7. Hologic, Inc.
    • 11.2.8. Agilent Technologies
    • 11.2.9. Myriad Genetics
    • 11.2.10. Danaher Corporation
    • 11.2.11. Siemens Healthineers
    • 11.2.12. Sysmex Corporation
    • 11.2.13. Becton, Dickinson and Company (BD)
    • 11.2.14. Genomic Health
    • 11.2.15. Epigenomics AG
    • 11.2.16. Bio-Techne Corporation
    • 11.2.17. Natera, Inc.
    • 11.2.18. Guardant Health
    • 11.2.19. Exact Sciences Corporation
    • 11.2.20. Biocept, Inc.

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us